Replies to post #17642 on Cel Sci Corporation (CVM)

[alexander77]

Let me help you as a professional in the medical field:
1. Multikine is indicated as first in line treatment of H&N cancer and NOT for recurrent H&N cancer
2. Multikine is indicated for use PRIOR to surgery and possible chemo ...

Therefore Multikine is unique and as groundbreaking as CAR-T cells. If successful in P3, we may expect a buyout for not less than $4 billion